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Objective. To assess the impact of cyclo-
phosphamide (CYC) on the health-related quality of
life (HRQOL) of patients with scleroderma after 12
months of treatment.
Methods. One hundred fifty-eight subjects partic-
ipated in the Scleroderma Lung Study, with 79 each
randomized to CYC and placebo arms. The study eval-
uated the results of 3 measures of health status: the
Short Form 36 (SF-36), the Health Assessment Ques-
tionnaire (HAQ) disability index (DI), and Mahler’s
dyspnea index, and the results of 1 preference-based
measure, the SF-6D. The differences in the HRQOL
between the 2 groups at 12 months were calculated using
a linear mixed model. Responsiveness was evaluated
using the effect size. The proportion of subjects in each
treatment group whose scores improved at least as
much as or more than the minimum clinically important
difference (MCID) in HRQOL measures was assessed.
Results. After adjustment for baseline scores,
differences in the HAQ DI, SF-36 role physical, general
health, vitality, role emotional, mental health scales,
and SF-36 mental component summary (MCS) score
were statistically significant for CYC versus placebo (P
< 0.05). Effect sizes were negligible (<0.20) for all of the
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scales of the SF-36, HAQ DI, and SF-6D at 12 months.
In contrast, a higher proportion of patients who re-
ceived CYC achieved the MCID compared with placebo
in the HAQ DI score (30.9% versus 14.8%), transitional
dyspnea index score (46.4% versus 12.7%), SF-36 MCS
score (33.3% versus 18.5%), and SF-6D score (21.3%
versus 3.8%).
Conclusion. One year of treatment with CYC
leads to an improvement in HRQOL in patients with
scleroderma lung disease.
The Scleroderma Lung Study (SLS) (1) is a
double-blind, randomized, placebo-controlled trial of
the effects of oral cyclophosphamide (CYC), adminis-
tered for 1 year, on the course of forced vital capacity
(FVC) (% predicted) in patients with evidence of active
systemic sclerosis (SSc; scleroderma)–related interstitial
lung disease (ILD), or scleroderma lung disease (SLD).
The study showed that CYC produced a statistically
significant, albeit modest, improvement in the 12-month
FVC % predicted relative to placebo. In addition, results
of the SLS showed a beneficial effect of CYC on the
health-related quality of life (HRQOL). We have previ-
ously described in detail the baseline correlates of
HRQOL from the SLS (2); the present report describes
the impact of treatment on the change in the HRQOL of
participants in the SLS from baseline to 12 months
following initiation of the study drug by treatment
assignment.
Study of HRQOL has originated from 2 funda-
mentally different approaches: health status assessment
and health value/preference/utility assessment (3,4).
Generally, health status measures describe a person’s
functioning in 1 or more domains (e.g., physical func-
tioning and mental well-being). The SLS evaluated
results obtained using 3 measures of health status: the
Short Form 36 (SF-36), a generic measure; the Health
Assessment Questionnaire (HAQ) disability index (DI),
a musculoskeletal-targeted measure; and Mahler’s dys-
pnea index, a dyspnea measure.
In contrast, health value/preference/utility mea-
sures assess the value or desirability of a state of health
against an external metric (5) and summarize HRQOL
using a single number. Preference-based measures can
be determined either directly via a face-to-face interview
with a subject or indirectly based on an individual’s
responses to a health status questionnaire. There are 2
major families of utilities: direct and indirect (or multi-
attribute) (4). The direct preference–based scores can be
assessed using the standard gamble (the risk of death,
usually, that one would be willing to take to improve a
state of health), the time tradeoff, and the rating scale
(6). Indirect preference–based scores use direct utility
scores from a representative general population sample
for a particular health state, and these scores are then
applied to different health states captured by health
status measurement instruments to derive a single score
(7). The SF-6D, an example of an indirect measure (8),
derives preference-based scores from the SF-36.
A recent advancement in the study of HRQOL is
the estimation of minimum clinically important differ-
ence (MCID), the smallest improvement in the score of
a HRQOL measurement instrument that patients per-
ceive as beneficial and that may lead to a change in
disease management (9). MCID can provide a bench-
mark for future design of SSc clinical trials by helping
researchers and clinicians understand whether differ-
ences in HRQOL scores between 2 treatment groups are
significant, or if changes within 1 group over time are
clinically meaningful (4,10).
PATIENTS AND METHODS
Patient selection. Patients with SSc, as defined by the
American College of Rheumatology (formerly, the American
Rheumatism Association) classification criteria (11), and a
disease duration of 7 years (with onset defined as the date of
the first typical non–Raynaud’s phenomenon manifestation)
were included in the current study. Other inclusion criteria
were as follows: FVC 85% of predicted, dyspnea on exertion
(grade 2 or higher on the magnitude of task component of
Mahler’s baseline dyspnea index [BDI]), and evidence of
alveolitis on bronchoalveolar lavage (neutrophils 3%, eosino-
phils 2%) and/or ground-glass opacification on high-
resolution computed tomography (2). The complete inclusion
and exclusion criteria were recently published (1).
Health status measurement instruments. Health sta-
tus was assessed using SF-36 version 2, the HAQ DI, and
Mahler’s dyspnea index. The SF-36 is a generic measure of
HRQOL consisting of 8 scales assessing 36 items (12,13). In
addition, it includes a single item that assesses health transi-
tion. The 8 SF-36 scales can be summarized into physical
component summary (PCS) and mental component summary
(MCS) scores. The 8 scales and summary scores are standard-
ized to responses from the US general population, for which
the mean score is 50 and the standard deviation is 10 (14). We
used the SF-36 with a standard (4-week) recall period. The
MCID for the SF-36 summary scores is between 2.5 and 5.0 in
different arthritides (15–17) (Table 1).
The HAQ DI is a disease-specific, musculoskeletal-
targeted measure designed to assess functional ability in
arthritis (18). It is a self-administered 20-question instrument
designed to assess a patient’s level of upper and lower extrem-
ity functioning. The HAQ DI score is determined by summing
the highest score in each of the 8 domains and dividing the sum
by 8, yielding a score ranging from 0 (no disability) to 3 (severe
disability). In the original HAQ DI, an additional grade of
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difficulty was added for patients using assistive/adaptive de-
vices (such as canes or walkers). For consistency with other
recent studies of SSc (19,20), the patients’ responses were not
modified for use of assistive/adaptive devices. An improvement
of 0.14 and 0.22 in the HAQ DI score is considered to be
the MCID in patients with SSc (10) and rheumatoid arthritis
(21), respectively.
Mahler’s dyspnea index allows patients to assess their
own level of dyspnea (22). Dyspnea at baseline is assessed
using the BDI. Scores on the BDI depend on ratings of 3
different categories: functional impairment, magnitude of task,
and magnitude of effort. Limitation of ability in each of these
3 categories is graded from 0 (severe) to 4 (unimpaired). The
ratings of the 3 categories are added to produce the total
baseline score, ranging from 0 (severe) to 12 (no dyspnea). The
transitional dyspnea index (TDI) assesses the change in dys-
pnea in each of the 3 categories, with scores ranging from 3
(major deterioration) to 3 (major improvement) for each
domain, with the TDI focal score being the sum of scores in the
3 domains (9 to 9). An improvement of 1 unit in the TDI
is considered to be the MCID (23).
Dyspnea was also assessed using the breathing visual
analog scale (VAS; 0–100 mm), in which patients assessed, on
a continuous scale, their own degree of difficulty in performing
daily activities due to shortness of breath.
Preference-based measure. In the SF-6D (24),
preference-based scores are derived from the SF-36. The
SF-36 was revised into a health state classification system
consisting of 6 dimensions (physical function, role limitation,
social function, pain, mental health, and vitality), with a single
HRQOL score derived from 11 items of the SF-36, covering
the 6 dimensions. To assess preferences for the multi-attribute
health states defined by the SF-6D, Brazier et al (24) used an
interviewer-administered standard gamble in a representative
sample from the UK. The weights for the US population have
not been developed. The SF-6D scores ranged from 0.29 to
1.00, with a score of 1.00 indicating perfect or full health (24).
An improvement of 0.041 in the SF-6D score was considered to
be the MCID (25).
Statistical analysis. We analyzed the HRQOL data
using the approach proposed by Osoba and colleagues (26).
Baseline descriptive statistics for the SF-36, HAQ DI, BDI,
and SF-6D scores, and the percentage with floor and ceiling
effects, were calculated. Floor and ceiling effects are the
percentages of respondents scoring at the lowest and highest
possible scale levels. These effects can influence responsive-
ness because they may limit a change in score over time (27).
The baseline scores between the 2 groups were com-
pared using Student’s t-test. The instruments were adminis-
tered every 3 months; we assessed the proportion of subjects in
the CYC and placebo groups who completed the instruments
at months 0, 3, 6, 9, and 12. Internal consistency reliability for
multi-item scales was estimated using Cronbach’s alpha (28),
with   0.70 considered satisfactory for group comparisons
(28). We calculated the differences in the HRQOL measures
between the 2 groups at 12 months using a linear mixed model
and adjusting for the baseline value (29,30). Unadjusted
strengths of association between HRQOL measures and phys-
iologic impairment (FVC % predicted and diffusing capacity
for carbon monoxide [DLCO] % predicted) at baseline were
assessed using Pearson’s correlation coefficients and inter-
preted as proposed by Franzblau (31): 0.0–0.20  no correla-
tion, 0.21–0.40  low degree of correlation, 0.41–0.60 
moderate degree, 0.61–0.80  marked degree, and 0.81–
1.00  high degree.
Because the number of patients in a study can affect
statistical significance, we examined clinical significance in 2
additional ways, by calculating effect size and the proportion of
patients whose change was greater than the MCID (32).
Responsiveness to change was evaluated using the effect size
(27). Effect size was assessed using the following formula:
MCYC  MPLAC/SDPLAC at baseline,
where MCYC  MPLAC is the average difference at month 12
between the CYC and placebo arms. Cohen’s guide for
interpreting effect size for HRQOL data is that a value of
0.20–0.49 represents a small change, 0.50–0.79 a medium
change, and 0.80 a large change (20,33).
We assessed the proportion of patients whose SF-36
summary score improved by 5 units from baseline to month 12,
the proportion of patients whose HAQ DI score improved by
0.14 and 0.22, the percentage of patients whose TDI
changed by 1 unit, and the proportion of patients whose
SF-6D score improved by 0.041. The aforementioned cut
points were selected a priori (Table 1). Based on the propor-
tion of patients whose scores improved at least as much as or
more than the MCID, we calculated the number needed to
treat (NNT) (34) in order to achieve, on average, 1 patient with
improved HRQOL:
NNT  1/ImprovedCYC/TotalCYC
 ImprovedPLACEBO/TotalPLACEBO)  100.
As suggested by Osoba and colleagues (35), we did not use the
Bonferroni adjustment because it assumes that the variables
being tested are completely independent of each other; how-
ever, some SF-36, HAQ DI, and Mahler’s dyspnea index scales
are moderately correlated (13,36,37). Statistical analyses were
performed using SAS software, version 8.02 (SAS Institute,
Cary, NC). P values less than 0.05 were considered significant.
RESULTS
The main findings of the SLS have recently been
published (1). Briefly, the mean  SD age of the study
population was 48.5  12.3 years, most of the partici-
pants were women (71.0%), and the patients had a
mean  SD disease duration of 3.1  2.1 years, mild
functional disability as assessed by the HAQ DI (0.82 
Table 1. Minimum clinically important difference (MCID) scores
for the HRQOL measurement instruments*
Instrument MCID score
SF-36 summary scores 2.5–5.0
Health Assessment Questionnaire disability index
Systemic sclerosis 0.14
Rheumatoid arthritis 0.22
Mahler’s dyspnea index 1.0
SF-6D 0.041
* HRQOL  health-related quality of life; SF-36  Short Form 36.
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0.69), and moderate dyspnea as assessed by Mahler’s
BDI (5.68  1.89) (Table 2). On average, the partici-
pants rated their physical and mental health as 1.7 SD
and 0.1 SD, respectively, below that of the adjusted
general US population (4). The SF-6D score was 0.63; in
other words, on average, the participants in the SLS
rated their health as 63% of perfect health.
Comparison of HRQOL scores in the CYC and
placebo groups at baseline. At baseline, the mean HAQ
DI score was significantly higher in the CYC group
(0.95  0.66) compared with the placebo group (0.71 
0.70) (P  0.03), whereas the SF-36 role physical (38.1 
13.0) and mental health (50.2  10.1) scores were
numerically higher in the placebo group compared with
the CYC group (34.3  11.5 and 47.3  10.2; P  0.05
and P  0.07), respectively. Otherwise, there were no
statistically significant differences in the HRQOL mea-
sures between the 2 groups (Table 2).
Reliability. Floor effects were more common in
the HAQ DI (13.1%) than the BDI (1.24%); no floor
effect was seen for the SF-36, SF-36 PCS, or SF-36 MCS
scores. There were no ceiling effects for the 3 instru-
ments. Internal consistency reliability scores were ac-
ceptable for all 3 measures: Cronbach’s alpha was 0.90
for the total HAQ DI score, 0.81 for the total BDI score,
and ranged from 0.89 for the social functioning scale to
0.90 for the mental health scale of the SF-36.
Change in the HRQOL over 12 months. The
percentage of patients who completed the HRQOL
measures (calculated as the percentage of patients with
FVC % predicted data available at each followup visit)
in the CYC and placebo groups, respectively, was 88.9%
versus 90.1% at 3 months, 88.9% versus 88.9% at 6
months, 83.9% versus 80.3% at 9 months, and 85.2%
versus 80.3% at 12 months. The difference was not
statistically significant at any time point and therefore no
statistical modeling was performed for missing data (38).
Association between HRQOL and physiologic mea-
sure scores at 12 months. SF-36 PCS and breathing VAS
showed a low degree of correlation with FVC % pre-
dicted and DLCO % predicted, SF-36 MCS showed no
correlation with FVC % predicted or DLCO % pre-







Age, years 48.5  12.3 48.8  12.2 48.2  12.4
% female 71.0 76.5 64.6
SSc duration, years 3.1  2.1 3.1  2.3 3.1  1.9
% with diffuse SSc 58.6 61.4 55.7
FVC, % predicted 68.1  11.3 67.8  12.9 68.4  12.1
Skin score (range 0–51) 14.7  10.9 15.4  11.3 14.0  10.5
Diffuse SSc 21  10.3 21.6  9.4 20.4  9.8
Limited SSc 5.7  3.5 5.8  3.3 5.6  3.4
SF-36
Physical function 34.43  11.32 33.2  11.0 35.7  11.6
Role physical 36.17  12.38 34.3  11.5 38.1  13.0
Body pain 41.97  10.55 41.4  10.6 42.5  10.5
General health 35.71  10.32 35.7  10.3 35.7  10.3
Vitality 40.24  11.31 39.3  10.04 41.2  12.5
Social function 43.94  12.23 43.8  12.3 44.1  12.2
Role emotional 45.26  12.69 44.1  12.8 46.5  12.6
Mental health 48.74  10.24 47.3  10.2 50.2  10.1
SF-36 PCS 33.43  10.74 32.6  10.8 34.2  10.7
SF-36 MCS 49.65  10.53 48.7  10.5 50.6  10.5
HAQ DI 0.82  0.69 0.95  0.66† 0.71  0.70
Mahler’s BDI focal score (0–12) 5.7  1.89 5.7  1.81 5.7  1.96
Functional impairment score (0–4) 1.74  0.84 1.72  0.78 1.76  0.89
Magnitude of task score (0–4) 1.99  0.68 1.99  0.72 1.99  0.65
Magnitude of effort score (0–4) 1.97  0.70 1.99  0.69 1.96  0.71
Breathing VAS 28.35  26.20 27.39  24.91 29.29  27.54
SF-6D 0.63  0.10 0.63  0.10 0.64  0.09
* Except where indicated otherwise, values are the mean  SD. For the Short Form 36 (SF-36), Mahler’s
dyspnea index score, and SF-6D, higher scores indicate better health, better breathing, and greater
desirability of one’s current health state, respectively. For the Health Assessment Questionnaire (HAQ)
disability index (DI), a higher score indicates greater functional disability. CYC  cyclophosphamide;
SSc  systemic sclerosis; FVC  forced vital capacity; PCS  physical component summary; MCS 
mental component summary; BDI  baseline dyspnea index; VAS  visual analog scale.
† P  0.03 versus placebo.
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dicted, and TDI had a moderate degree of correlation
with FVC % predicted and a low degree with DLCO %
predicted (Table 3).
We assessed the change in the HRQOL using 3
different statistical approaches: statistical significance,
responsiveness index, and the proportion of patients
whose scores improved more than the MCID.
Statistical significance. After adjustment for base-
line scores and application of a linear mixed model, the
difference in the HAQ DI score, SF-36 role physical,
general health, vitality, role emotional, and mental
health scores, and the SF-36 MCS score between the
CYC and placebo arms was statistically significant at 12
months (P 	 0.05) (Table 4). Since the TDI itself
represents a change score and therefore was not admin-
istered at baseline, we assessed the impact of CYC on
the TDI using the generalized estimating equation (39).
CYC had a statistically significant favorable impact on
the TDI (P 	 0.0001) (Table 4).
Responsiveness index. In comparison, the effect
sizes were negligible (	0.20) for all of the scales and
summary scores of the SF-36 and the HAQ DI at
12 months. The effect size was not calculated for the
TDI.
Table 3. Correlation coefficients between health-related quality of life (HRQOL) and physiologic measure change scores at 12 months*
HRQOL measures Physiologic measures







SF-36 PCS 1.00 0.14 0.42† 0.37† 0.27† 0.45† 0.25† 0.24†
SF-36 MCS 1.00 0.12 0.19† 0.26† 0.52† 0.13 0.03
HAQ DI 1.00 0.29† 0.33† 0.24† 0.34† 0.18
TDI 1.00 0.30† 0.37† 0.41† 0.31†
Breathing VAS 1.00 0.23† 0.32† 0.24†
SF-6D 1.00 0.28† 0.32†
FVC % predicted 1.00 0.52†
DLCO % predicted 1.00
* SF-36  Short Form 36; PCS  physical component summary; MCS  mental component summary; HAQ DI  Health Assessment
Questionnaire disability index; TDI  transitional dyspnea index; VAS  visual analog scale; FVC  forced vital capacity; DLCO  diffusing
capacity for carbon monoxide.
† P 	 0.05.
Table 4. Differences in the HRQOL scores between CYC-treated and placebo-treated patients at 12 months*
CYC (month 12 
baseline score)
Placebo (month 12 
baseline score) Difference P
SF-36
Physical function 0.56 0.57 0.009 0.99
Role physical 3.11 1.03 4.4 	0.001
Body pain 0.60 0.43 1.03 0.21
General health 0.89 0.58 1.48 0.03
Vitality 2.22 0.31 1.91 0.009
Social function 0.75 0.22 0.97 0.31
Role emotional 1.99 1.52 3.52 0.005
Mental health 1.51 0.56 2.07 0.006
SF-36 PCS 0.08 0.07 0.15 0.84
SF-36 MCS 2.12 0.56 2.67 0.003
HAQ DI 0.07 0.11 0.17 0.0001
Mahler TDI focal score (9 to 9)† 1.38 1.25 2.63 	0.0001
Functional impairment (3 to 3)† 0.37 0.34 0.71 0.001
Magnitude of task (3 to 3)† 0.62 0.44 1.06 0.0001
Magnitude of effort (3 to 3)† 0.39 0.47 0.86 0.0001
Breathing VAS 2.60 3.22 0.62 0.90
SF-6D 0.02 0.01 0.01 0.54
* For the SF-36 scales and summary scores and the BDI, a positive score indicates improvement, and for the
HAQ DI, a negative score indicates improvement. The numbers in the difference column may not be exact due
to rounding to the nearest decimal. See Table 2 for definitions.
† The generalized estimating equation model was used to assess statistical significance.
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Proportion of patients whose scores improved more
than MCID. Although the effect size did not show any
difference in the average scores between the CYC and
placebo groups, a higher proportion of patients who
took CYC compared with placebo achieved MCID in
the SF-36 MCS score (33.3% versus 18.5%), HAQ DI
score (30.9% versus 14.8%), and TDI score (46.4%
versus 12.7%) (Table 5). Also, a greater proportion of
patients who took CYC showed improvement in the
health transition scale of the SF-36, a single-item mea-
sure determined by response to the question, “Com-
pared to one year ago, how would you rate your health
in general now?” In response, 47.0% of the patients who
took CYC rated their health as somewhat better or
much better, compared with 18.2% in the placebo group
(P 	 0.001). In comparison, only 24.2% in the CYC
group rated their health somewhat worse or much worse,
compared with 38.7% in the placebo group (P  0.01).
The proportion of patients whose scores im-
proved more than the MCID was then used to assess the
NNT (34,40) in order to achieve, on average, 1 patient
with improved HRQOL. For the HAQ DI, this was
calculated as follows (Table 5):
NNT  1/31%  15%
  100  6.25.
In other words, one would need to treat 6 or 7 patients
with CYC to have 1 person experience a clinically
meaningful improvement in his or her functional ability
greater than that expected with placebo. Similarly, one
would need to treat 3 patients with CYC to have 1
person experience a clinically meaningful difference in
dyspnea compared with placebo (NNT  1/[46% 
13%]  100  3).
Similar to health status measures, the SF-6D
score showed a low degree of correlation with FVC %
predicted and DLCO % predicted. At 12 months, the
average SF-6D score was 0.65 in the CYC group and
0.63 in the placebo group and there was no statistically
significant difference between the groups (P  0.54).
The difference in effect size between the 2 treatment
groups was negligible. In comparison, a higher propor-
tion of patients who took CYC compared with placebo
achieved MCID in the SF-6D score (21.3% versus
3.8%); one would need to treat 5 or 6 patients with CYC
to have 1 person experience clinically meaningful im-
provement in his or her desirability of the current health
state than expected with placebo.
DISCUSSION
The SLS is the first randomized, placebo-
controlled trial to show a statistically significant, al-
though modest, beneficial effect of CYC on the change
in FVC % predicted compared with placebo after 12
months (1). The favorable effect of CYC on FVC was
accompanied by parallel improvement in HRQOL mea-
sures, including functional disability, shortness of
breath, and mental well-being, at the end of the 1-year
study (1).
At baseline, the participants had mild functional
disability as assessed by the HAQ DI (mean  SD
0.82  0.69) and moderate dyspnea as assessed by
Mahler’s BDI (5.68  1.89) (Table 2). In addition, the
participants rated their physical and mental health 1.7
SD and 0.1 SD, respectively, below that of the general
US population, which is consistent with the results of
another study on SSc in which patients had moderate
impairment in their SF-36 PCS score but a normal or
near-normal SF-36 MCS score (20). Although this was
not formally assessed, the normal SF-36 MCS score may
represent a psychological adjustment to the typically
slow progression of SSc (41).
HRQOL experts recommend the use of both
disease-specific and generic HRQOL measures in clini-
cal trials (4,32). The HAQ DI, a musculoskeletal-
targeted measure, was able to demonstrate a statistically
significant and clinically meaningful difference in func-
tional ability between the CYC and placebo arms at 12
months. In contrast, changes in the SF-36 physical
functioning scale and the SF-36 PCS were not signifi-
cantly different between the 2 groups at 12 months.
However, changes in the SF-36 vitality, role emotional,
and mental health scales and the SF-36 MCS were
significantly different between the 2 groups and favored
CYC.
Since improvements in the SF-36 were most
Table 5. Proportion of patients in the CYC and placebo groups





SF-36 PCS score 5 units 21.0 18.5 0.65 40.00
SF-36 MCS score 5
units
33.3 18.5 0.09 6.75
HAQ DI score 0.14 30.9 14.8 0.05 6.25
HAQ DI score 0.22 30.9 14.8 0.05 6.25
TDI score 1.0 unit 46.4 12.7 0.0001 3.00
SF-6D score 0.041 21.3 3.8 0.001 5.71
* CYC  cyclophosphamide; MCID  minimal clinically important
difference; NNT  number needed to treat; SF-36  Short Form 36;
PCS  physical component summary; MCS  mental component
summary; HAQ DI  Health Assessment Questionnaire disability
index; TDI  transitional dyspnea index.
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prominent in mental functioning scores, our findings
suggest that improvement in the pulmonary and/or
skin/musculoskeletal manifestations of ILD has a signif-
icant impact on mental well-being. This study confirms
the opinion that disease-specific and generic HRQOL
measures complement each other. Also, the associa-
tions between patient-reported outcomes and physio-
logic measures are only modest (42–44). The correlation
coefficients between HRQOL measures and physio-
logic measures ranged from none (0.03) to a moderate
degree (0.41), confirming previous observations that
HRQOL and physiologic measures complement each
other (42–44).
Analysis at the group level showed that treatment
with CYC led to a statistically significant improvement
in the HAQ DI, TDI, and SF-36 role physical, general
health, vitality, role emotional, and mental health scales
compared with placebo. Since statistical significance is
dependent on the sample size, experts suggest also using
a responsiveness index, such as effect size, to assess the
clinical significance of such change (45). In contrast to
the statistically significant results, effect sizes of CYC on
functional disability, dyspnea, and physical and mental
functioning scales were negligible (all were 	0.20). At a
group level, a change of 0.20–0.49 in effect size is
considered a clinically meaningful improvement (46,47).
We also assessed the proportion of patients be-
tween the 2 groups whose scores improved more than
the MCID (4) at 1 year. In contrast to negligible effect
size results that assess average scores, the scores of a
higher proportion of patients who took CYC improved
more than the MCID in HRQOL measures, including
the HAQ DI score, TDI score, and SF-36 MCS score,
compared with placebo.
We used the proportion of patients whose scores
improved more than the MCID to assess the NNT
(34,40) in order to achieve, on average, 1 patient with
improved HRQOL. This ranged from 3 patients for TDI
to 40 patients for SF-36 PCS. In other words, one would
need to treat 3 patients with CYC to have 1 person
experience clinically meaningful improvement in dys-
pnea compared with placebo. We found these changes
to be robust despite the group differences in baseline
scores since ceiling effects did not occur.
Our results show a disparity between the modest
physiologic benefit in SLS and the more obvious im-
provement in HRQOL measures in general, and breath-
lessness in particular. In other chronic respiratory dis-
eases, small changes in lung function can have a
significant clinical impact on symptoms and exercise
tolerance (48–50). It is therefore not surprising that the
modest changes in lung function parameters are accom-
panied by a more obvious and clinically meaningful
improvement in dyspnea.
There are several possible mechanisms that
might explain the disparity between the rather marked
improvement in dyspnea and the small improvement in
FVC in our SLS ILD subjects, such as a reduction in
inflammation in the lung, leading to decreased J recep-
tor stimulation and decreased excessive drive to breathe,
thus reducing dyspnea; reduction in skin thickness that
could improve chest wall compliance and the exertion
required for breathing; and musculoskeletal improve-
ment that could lead to greater mobility, with a favor-
able “training” effect that improves exercise tolerance.
Health status measurement instruments can be
used to inform and monitor outcomes in clinical encoun-
ters, monitor population health, estimate the burden of
different conditions, and as end points in clinical trials
(3,4). However, preference-based measures serve as
“quality-adjustment factors” for calculating quality-
adjusted life years (QALYs) in decision and cost-
effectiveness analyses that are used in resource alloca-
tion (3). A QALY takes into account both the quantity
and quality of life generated by health care interventions
(51). For the SF-6D, a higher proportion of patients
treated with CYC had a clinically meaningful change
(21%) compared with those in the placebo group (4%;
P  0.001). However, the difference in the average
SF-6D scores at 1 year was not statistically significant
(0.65 in the CYC group versus 0.63 in the placebo group;
P  0.54). The reason for this discrepancy is likely
related to the side effect profile of CYC. If significant
numbers of individuals have adverse health conse-
quences while at the same time clinical benefit is
achieved in those able to take the medication, then this
seemingly paradoxical outcome is understood. Since
cost-effectiveness analyses incorporate average scores,
from a societal perspective this may result in an unfa-
vorable cost-effectiveness ratio for the use of CYC in the
treatment of SSc-associated ILD.
Our study has some limitations. First, we cannot
determine to what extent the beneficial effects of CYC
on HRQOL are due to the modest improvement in lung
function as measured by the FVC % predicted and/or
improvement in extrapulmonary manifestations, such as
skin thickness, muscle strength, and arthritis. The im-
provement in HRQOL may well be due to a combina-
tion of both since the SLS showed a statistically signifi-
cant improvement in both FVC % predicted and skin
score (1). Whether this beneficial effect of CYC on the
FVC and HRQOL measures will continue during the
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second year of the SLS treatment will be determined in
future analyses.
Second, Mahler’s dyspnea index was developed
and validated in patients with chronic obstructive pul-
monary disease (22,23). Although the dyspnea index has
been previously used in patients with ILD (52), it has not
been subjected to psychometric rigor in this latter group
of patients. While this study could have provided the
platform with which to validate Mahler’s dyspnea index
in ILD, unfortunately no respiratory-specific question-
naire (such as St. George’s Respiratory Questionnaire)
was administered.
Third, floor effects were more common in HAQ
DI scores (13.1%) than in other measures. In other
words, 13% of the participants did not report any
functional disability. This is of significance since floor
effects can limit the assessment of responsiveness to
change (20,27). A lower proportion of floor effects
(4.5% of the participants) in the HAQ DI score was seen
in another SSc clinical trial (20) in which all participants
had early diffuse SSc, compared with the inclusion of
subjects with both limited and diffuse SSc in the current
study.
In conclusion, CYC led to an improvement in the
HRQOL of patients with SLD. Patient-reported out-
comes and physiologic measures complemented each
other, and we present different statistical methods that
can be used to assess HRQOL in a randomized clinical
trial.
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